Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients-a randomized crossover trial

Peritoneal Dialysis International

Volumn 32, Issue 5, 2012, Pages 507-515

  Li, Yun ^a   Xie, Qiong hong ^a   You, Huai zhou ^a   Tian, Jing ^a   Hao, Chuan ming ^a   Lin, Shan yan ^a   Zhu, Tong ying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adipocytokines; Inflammation; Insulin resistance; Lipid dysmetabolism; Pioglitazone

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FUROSEMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; RESISTIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEG EDEMA; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM RESTRICTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM DISORDERS; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84865135385     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2011.00116     Document Type: Article

References (26)

1. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl 2006; (103):S3-11.
2. Huang CC, Cheng KF, Wu HD. Survival analysis: comparing peritoneal dialysis and hemodialysis in Taiwan. Perit Dial Int 2008; 28(Suppl 3):S15-20.
3. Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int 2009; 29(Suppl 2):S145-8.
4. Shen Y, Peake PW, Kelly JJ. Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005; 10:599-605.
5. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24:327-39.
6. Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220:143-51.
7. Cocchi R, Viglino G, Cancarini G, Catizone L, Favazza A, Tommasi A, et al. Prevalence of hyperlipidemia in a cohort of CAPD patients. Italian Cooperative Peritoneal Dialysis Study Group (ICPDSG). miner electrolyte metab 1996; 22:22-5.
8. Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, et al. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 2001; 21:282-9.
9. Valdivielso P, Sánchez-Chaparro MA, Calvo-Bonacho E, Cabrera-Sierra M, Sainz-Gutiérrez JC, Fernández-Labandera C, et al. Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. Atherosclerosis 2009; 207:573-8.
10. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type2 diabetes. Diabetologia 2005; 48:83-95.
11. Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005; 54:1236-42.
12. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 2003; 42:774-80.
13. Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001; 50:1294-300.
14. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62:1463-80.
15. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
16. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24:710-19.
17. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type2 diabetes mellitus. Coron Artery Dis 2001; 12:413-23.
18. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547-54.
19. Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug targets Inflamm Allergy 2002; 1:243-8.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094-9.
21. Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc 2008; 83:333-42.
22. Riera-Guardia N, Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes obes metab 2008; 10:367-75.
23. Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Bárány P, Lonnqvist F, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69:596-604.
24. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 2009; 15:529-36.
25. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17:3482-90.
26. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009; 131:298-304.